EUVIMEDEUVIMED entdecken
Crossref

Current Resistance of HIV-1 Strains Isolated in Volunteer Blood Donors in Gabon

Christian Mangala iD, Denis Maulot-Bangola, Alain Moutsinga, Anges Gar Wamba, Serge Christian Okolongo-Mayani, Joseph Fokam

AIDS Research and Human Retroviruses · 2024

DOI: 10.1089/aid.2023.0080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AIDS Research and Human Retroviruses, 2024. Verfasst von Christian Mangala und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Public Health Laboratory, Libreville, Gabon. Hauptthemen laut MEDLINE: HIV-1, Blood Donors, Drug Resistance, Viral, HIV Infections. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Detection of drug resistance mutations (DRMs) and HIV-1 subtypes ensures effective therapeutic management for HIV-infected individuals. In Gabon, data on DRMs are very little available in the population of people living with HIV and also among voluntary HIV-positive blood donors. This study aimed to study subtypes and DRMs in HIV-1-positive volunteer blood donors in Gabon. A cross-sectional study was carried out at the National Blood Transfusion Center of Gabon. A purposive sampling method was used to collect 128 HIV-1 seropositive blood samples. Viral RNA was extracted on real-time PCR (Abbott 2000 ® ), and sequencing was performed on ABI 3500 (Hitachi ® ). SPSS version 21.0 software was used for statistical analysis. Of the 128 seropositive volunteer donors included, men and the 29–39-age group were more representative at 78.9% and 49.2%, respectively. Eighty-two samples were sequenced. The majority strains identified were subtype A, subtype F, subtype G, CRF02_AG, and CRF45_cpx. The resistance mutations identified were K103N, L210W, E138G, V179D, V179T, and M46L. The prevalence of resistant subtypes was 25.6%. CRF02_AG strains exhibited high-level resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs), including efavirenz and nevirapine. The study identified major DRMs in reverse transcriptase and protease that confer high-level resistance to most NNRTIs, nucleoside reverse transcriptase inhibitors, and protease inhibitors. CRF02_AG was more predominant, and the frequency of resistant subtypes was high. However, these data will contribute to the therapeutic choice during the initiation of antiretroviral treatment in treatment-naive patients in Gabon.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Blood DonorsDrug Resistance, ViralHIV InfectionsHumansGabonMaleCross-Sectional StudiesAdultFemaleYoung AdultMiddle AgedRNA, ViralGenotypeAnti-HIV AgentsSequence Analysis, DNAPrevalenceMutation

Stichwörter der Autor:innen

GabonHIV-1drug resistance mutationssubtypesvolunteer donors

Substanzen

RNA, ViralAnti-HIV Agents

Autor:innen und Institutionen

  • National Public Health Laboratory, Libreville, Gabon.
  • Catholic University of Central Africa, Yaounde, Cameroon.
  • National Blood Transfusion Center, Libreville, Gabon.
  • Peyrie Medical Center, Libreville, Gabon.
  • Chantal Biya International Reference Center, Yaounde, Cameroon.

ORCID-Profile: Christian Mangala

Zitieren

APA

Mangala, C., Maulot-Bangola, D., Moutsinga, A., Wamba, A. G., Okolongo-Mayani, S. C., & Fokam, J. (2024). Current Resistance of HIV-1 Strains Isolated in Volunteer Blood Donors in Gabon. AIDS Research and Human Retroviruses. https://doi.org/10.1089/aid.2023.0080

Vancouver

Mangala C, Maulot-Bangola D, Moutsinga A, Wamba AG, Okolongo-Mayani SC, Fokam J. Current Resistance of HIV-1 Strains Isolated in Volunteer Blood Donors in Gabon. AIDS Research and Human Retroviruses. 2024. doi:10.1089/aid.2023.0080

BibTeX
@article{Mangala2024,
  author = {Mangala, Christian and Maulot-Bangola, Denis and Moutsinga, Alain and Wamba, Anges Gar and Okolongo-Mayani, Serge Christian and Fokam, Joseph},
  title = {Current Resistance of HIV-1 Strains Isolated in Volunteer Blood Donors in Gabon},
  journal = {AIDS Research and Human Retroviruses},
  year = {2024},
  doi = {10.1089/aid.2023.0080}
}
Kostenlos starten →